The continuous glucose monitoring devices market size was estimated at USD 13.66 billion in 2024 and is projected to reach USD 49.87 billion by 2033, growing at a CAGR of 15.44% from 2025 to 2033. The market’s rapid growth is primarily driven by increasing clinical needs, ongoing technological advancements, and the evolution of healthcare delivery models that emphasize patient-centric and continuous care.

A major factor contributing to this expansion is the rising global prevalence of diabetes, which has created a pressing need for more efficient, real-time glucose monitoring solutions. Traditional blood glucose monitoring methods are often invasive, intermittent, and inconvenient, leading to a shift toward CGM systems that offer continuous and automated glucose tracking. These systems enable better glycemic control and improve patients’ overall quality of life. According to the International Diabetes Federation (IDF), around 589 million adults worldwide were living with diabetes in 2024, highlighting the growing demand for advanced monitoring technologies.

CGM devices are minimally invasive and provide a convenient and effective approach to diabetes management. They continuously monitor blood glucose levels, allowing for the early detection of sharp fluctuations that could lead to hypoglycemia or hyperglycemia. These systems use sensors to collect glucose readings at regular intervals and transmit the data to diabetes management software via wireless connectivity. This real-time data helps patients and healthcare providers make informed decisions, promoting better disease management and lifestyle adjustments.

Common risk factors contributing to diabetes complications include smoking, obesity, physical inactivity, high blood pressure, and elevated cholesterol levels, which further emphasize the importance of effective monitoring. Continuous innovation by key market players is also fueling growth. For example, in January 2024, Medtronic received CE Mark approval in Europe for its MiniMed 780G system integrated with Simplera Sync—a next-generation, minimally invasive CGM sensor designed to work seamlessly with its automated insulin delivery pump. Such advancements continue to enhance the accuracy, comfort, and usability of CGM devices, driving their adoption globally.

Key Market Trends & Insights:

• North America dominated the global continuous glucose monitoring (CGM) devices market in 2024, capturing the largest revenue share of 56.8%. This strong regional presence is attributed to the high prevalence of diabetes, widespread adoption of advanced healthcare technologies, favorable reimbursement policies, and increased awareness regarding the benefits of continuous glucose monitoring. The region’s well-established healthcare infrastructure and strong presence of major industry players further support its market leadership.

• Within North America, the U.S. CGM devices industry is projected to grow at a significant CAGR over the forecast period. Factors driving this growth include increasing diabetes incidence, growing emphasis on preventive healthcare, and continuous product innovation by key manufacturers. Moreover, the integration of digital health technologies and mobile applications for real-time glucose tracking is enhancing user convenience and expanding the country’s adoption rate.

• Based on product type, the standalone CGM devices segment led the global market with the largest revenue share of 78.3% in 2024. The dominance of this segment is due to the growing preference for independent monitoring systems that do not require frequent calibration with blood glucose meters. Standalone devices offer continuous, accurate glucose readings, enabling better glycemic control and reducing the risk of complications, making them increasingly popular among both patients and healthcare professionals.

• In terms of connectivity, the Bluetooth segment accounted for the largest market share in 2024. The widespread use of smartphones and wearable devices has accelerated the adoption of Bluetooth-enabled CGM systems, allowing users to seamlessly sync and monitor glucose levels through mobile applications. This technology enhances patient engagement and facilitates remote monitoring by healthcare providers.

• Based on distribution channel, the pharmacies and e-commerce segment held the largest market revenue share in 2024. The easy availability of CGM devices through retail pharmacies and the growing popularity of online platforms have significantly improved accessibility for consumers. Additionally, increasing consumer preference for convenient purchasing options and doorstep delivery services has further fueled the dominance of this segment in the overall market.

Order a free sample PDF of the Continuous Glucose Monitoring Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 13.66 Billion

• 2033 Projected Market Size: USD 49.87 Billion

• CAGR (2025-2033): 15.44%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The continuous glucose monitoring (CGM) devices industry is highly competitive, characterized by the strong presence of leading companies such as Abbott Laboratories, DexCom, Inc., and Medtronic plc, which hold significant market positions globally. These companies continuously focus on innovation and strategic initiatives to strengthen their market share and enhance product performance.

To maintain their competitive edge, major players adopt a combination of organic and inorganic growth strategies, including new product launches, technological advancements, strategic collaborations, mergers, and regional expansions. Through these initiatives, companies aim to improve device accuracy, user convenience, and integration with digital health platforms. Additionally, expanding into emerging markets and forming partnerships with healthcare providers and technology firms allows these companies to address the unmet needs of diabetic patients more effectively.

Key Players

• DexCom, Inc.

• Abbott Laboratories

• Medtronic plc

• Senseonics Holdings, Inc.

• Insulet Corporation

• Tandem Diabetes Care

• Ascenia Diabetes Care (subsidiary of PHC Holdings)

• AgaMatrix, Inc

• GlucoRx Limited

• Zhejiang POCTech Co., Ltd.

• i-SENS, Inc.

• F. Hoffmann-La Roche Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The CGM devices market is poised for robust expansion, driven by increasing diabetes prevalence, rising demand for real-time glucose insights and evolving care pathways. Technological innovations—such as minimally invasive sensors, connectivity features and integration with digital health platforms—are enhancing patient access and usability. While regions with well-established healthcare systems currently dominate, emerging markets are set to contribute more as infrastructure and reimbursement frameworks mature. Overall, the market outlook is highly favourable, with scope for major growth across devices, connectivity and distribution channels.